Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia

被引：31
|
作者：
Coombs, Catherine C. [1 ]
Sallman, David A. [2 ]
Devlin, Sean M. [3 ]
Dixit, Shweta
Mohanty, Abhinita [5 ]
Knapp, Kristina [4 ]
Al Ali, Najla H. [2 ]
Lancet, Jeffrey E. [2 ]
List, Alan F. [2 ]
Komrokji, Rami S. [2 ]
Padron, Eric [2 ]
Arcila, Maria E. [5 ]
Klimek, Virginia M. [1 ]
van den Brink, Marcel R. M. [6 ]
Tallman, Martin S. [1 ,7 ]
Levine, Ross L. [1 ,4 ]
Rampal, Raajit K. [1 ]
Rapaport, Franck [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, 1275 York Ave, New York, NY 10021 USA
[2] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA
[3] Mem Sloan Kettering Canc Ctr, Dept Biostat & Epidemiol, 1275 York Ave, New York, NY 10021 USA
[4] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, 1275 York Ave, New York, NY 10021 USA
[5] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA
[6] Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, 1275 York Ave, New York, NY 10021 USA
[7] Weill Cornell Med Coll, New York, NY USA
来源：
HAEMATOLOGICA | 2016年 / 101卷 / 11期
关键词：
OLDER PATIENTS; AZACITIDINE; PHENOTYPE; DNMT3A; IMPACT; IDH2; CARE; AML;
D O I：
10.3324/haematol.2016.148999
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E457 / E460
页数：4
相关论文
共 50 条
  • [31] Management of Chemotherapy-Ineligible Acute Myeloid Leukemia: Beyond Hypomethylating Agent Monotherapy
    Stein, Eytan M.
    ONCOLOGY-NEW YORK, 2021, 35 (09): : 594 - 597
  • [32] Hypomethylating Agent/Venetoclax Versus Intensive Chemotherapy in Relapsed or Refractory Acute Myeloid Leukemia
    Jamy, Omer Hassan
    Worth, Sarah
    Rangaraju, Sravanti
    Bachiashvili, Kimo
    Vachhani, Pankit
    Bhatia, Ravi
    BLOOD, 2021, 138
  • [33] Hypomethylating agents as first-line therapy in acute myeloid leukemia (AML).
    Bailey, Samuel D.
    Gul, Zartash
    Slone, Stacey A.
    Van Meter, Emily Marie
    Lawson, Amber
    Raufi, Ali
    Hayslip, John W.
    Monohan, Gregory
    Howard, Dianna S.
    McDonagh, Kevin T.
    Alkadhimi, Zaid
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [34] Hypomethylating Chemotherapeutic Agents as Therapy for Myelodysplastic Syndromes and Prevention of Acute Myeloid Leukemia
    Sorrentino, Vincent G.
    Thota, Srijan
    Gonzalez, Edward A.
    Rameshwar, Pranela
    Chang, Victor T.
    Etchegaray, Jean-Pierre
    PHARMACEUTICALS, 2021, 14 (07)
  • [35] Outcome of Patients with Acute Myeloid Leukemia Following Failure of Front-Line Venetoclax Plus Hypomethylating Agent Therapy
    Ilyas, Rimal
    Johnson, Isla McKerrow
    McCullough, Kristen
    Al-Kali, Aref
    Alkhateeb, Hassan B.
    Begna, Kebede
    Mangaonkar, Abhishek A.
    Litzow, Mark R.
    Hogan, William J.
    Shah, Mithun, V
    Patnaik, Mrinal M. M.
    Pardanani, Animesh
    Tefferi, Ayalew
    Gangat, Naseema
    BLOOD, 2022, 140 : 1286 - 1287
  • [36] Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia
    Aldoss, Ibrahim
    Yang, Dongyun
    Pillai, Raju
    Sanchez, James F.
    Mei, Matthew
    Aribi, Ahmed
    Ali, Haris
    Sandhu, Karamjeet
    Al Malki, Monzr M.
    Salhotra, Amandeep
    Khaled, Samer
    Sun, Weili
    O'Donnell, Margaret
    Snyder, David
    Nakamura, Ryotaro
    Stein, Anthony S.
    Forman, Stephen J.
    Marcucci, Guido
    Pullarkat, Vinod
    AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (10) : E253 - E255
  • [37] Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia
    Saliba, Antoine N.
    John, August J.
    Kaufmann, Scott H.
    CANCER DRUG RESISTANCE, 2021, 4 (01) : 125 - 142
  • [38] Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts
    Srivastava, Pragya
    Paluch, Benjamin E.
    Matsuzaki, Junko
    James, Smitha R.
    Collamat-Lai, Golda
    Karbach, Julia
    Nemeth, Michael J.
    Taverna, Pietro
    Karpf, Adam R.
    Griffiths, Elizabeth A.
    LEUKEMIA RESEARCH, 2014, 38 (11) : 1332 - 1341
  • [39] Validation of the Charlson Comorbidity Index Model in Acute Myeloid Leukemia Treated with a Hypomethylating Agent and Venetoclax
    Bouligny, Ian
    Murray, Graeme
    Thuy Ho
    Gor, Juhi
    Zacholski, Kyle
    Wages, Nolan
    Grant, Steven
    Maher, Keri
    BLOOD, 2023, 142
  • [40] Immunomodulatory Effect of SGI-110, a Novel Hypomethylating Agent in Acute Myeloid Leukemia (AML)
    Stroopinsky, Dina
    Pyzer, Athalia Rachel
    Palmer, Kristen A.
    Coll, Maxwell D.
    Bar-Natan, Michal
    Rajabi, Hasan
    Somaiya, Poorvi
    Luptakova, Katarina
    Jain, Salvia
    McMasters, Malgorzata
    Levine, James D.
    Arnason, Jon
    Taverna, Pietro
    Kufe, Donald
    Avigan, David
    Rosenblatt, Jacalyn
    BLOOD, 2014, 124 (21)
12345